Shop by goal
Popular compounds
Research resources
Recently viewed
Is BPC-157 Banned? What the FDA Has and Hasn’t Done
Short answer: not in the way the word suggests. BPC-157 is a research-use-only compound, not a scheduled or criminalised substance. In 2023 the FDA’s compounding review kept BPC-157 off the 503A Bulks List for human-use compounding — the decision behind most “BPC-157 banned” headlines. It remains available as a laboratory reagent, it returns for FDA advisory committee discussion in July 2026 , and it is separately prohibited in tested sport by WADA.
“Is BPC-157 banned?” is a question shaped almost entirely by headlines, and the headlines compress a lot of nuance into one scary word. The accurate picture is more specific: BPC-157 was never approved as a medicine, a 2023 FDA decision limited its use in pharmacy compounding, and it sits in a research-use-only category today. Here is what actually happened.
BPC-157 is not a controlled substance
First, the most common misunderstanding: BPC-157 is not a scheduled drug like a narcotic. There is no blanket criminal “ban” on the molecule itself. It is supplied to laboratories as a research reagent, labelled research use only, not for human consumption. As with most research compounds, the legal line is determined by how it is marketed and used — selling or labelling it for human use is what creates regulatory exposure — not by mere possession of a labelled reagent. Our explainer on whether peptides are legal sets out that distinction.
The 2023 FDA compounding decision (the real story behind “banned”)
The source of most “BPC-157 banned” coverage is the FDA’s 2023 evaluation of substances nominated for use in pharmacy compounding. In that review, BPC-157 was not placed on the 503A Bulks List for human-use compounding; the agency raised concerns including limited safety characterisation and immunogenicity questions. In practice, that kept compounding pharmacies from preparing BPC-157 for people.
What “kept off the bulks list” means. It is a restriction on compounding for human use , not a criminalisation of the molecule. It actually reinforces the research-use-only category rather than contradicting it. We cover the decision in depth in our 2023 FDA peptide compounding explainer.
July 2026: BPC-157 is back on the FDA’s agenda
The story did not end in 2023. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee is scheduled to discuss BPC-157 bulk drug substances again (free base and acetate), with ulcerative colitis listed as the evaluated use, as part of a fresh review of several peptide-related substances for potential 503A Bulks List consideration.
Importantly, this is still a compounding review, not a drug-approval decision and not a reversal of a criminal ban (there was none). Whatever the committee recommends, it would not by itself make BPC-157 an FDA-approved medicine. The full agenda is covered in our FDA peptide review 2026 overview, and the regenerative angle in our BPC-157 and TB-500 review.
Is BPC-157 banned in sport?
Here the word “banned” is accurate. The World Anti-Doping Agency (WADA) prohibits BPC-157 at all times under category S0 (non-approved substances) of its Prohibited List. Any athlete in a tested sport who uses it risks an anti-doping violation and sanctions, independent of the compound’s research-use status. If you compete under WADA or a national anti-doping code, treat BPC-157 as prohibited.
“Banned” vs “not approved”: a useful distinction
Much of the confusion comes from blurring two separate ideas:
None of those is the same as a blanket criminal ban, and conflating them is exactly how “is BPC-157 banned?” turns into misinformation.
What this means if you research BPC-157
Treat BPC-157 as what it is: a research compound with an unsettled regulatory status and an active FDA review. Responsible suppliers position it for research use only and back it with a Certificate of Analysis. Be sceptical of any seller claiming BPC-157 is “FDA approved,” “unbanned,” or “cleared for human use” on the back of the 2026 meeting — none of those claims would be accurate.
Frequently Asked Questions
Is BPC-157 banned? Not as a scheduled/illegal substance. It is research-use-only; the FDA’s 2023 review kept it off the 503A Bulks List for human-use compounding, and WADA bans it in sport.
Did the FDA ban BPC-157 in 2023? The FDA kept it off the compounding bulks list for human use — a restriction on compounding, not a criminalisation of the molecule.
Could the July 2026 meeting “unban” it? It is a compounding-list review, not a criminal matter. Any recommendation would not make BPC-157 an approved medicine.
Related Reading
Source: the FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting agenda, and the WADA Prohibited List (category S0). External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
From the Lab - Peptides on LinkedIn & Facebook
Lab-Verified Research Compounds
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with the batch Certificate of Analysis published online.
At New-U, we believe better conversations start with better information. Research use only - all claims made on this site are for testing and research use only.
Research-grade · >99% HPLC purity · COA per lot
Buy BPC-157 from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.
PRECISION. PURITY. PERFORMANCE.
Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.
Shop
Research
Support
Ways to Pay
Shop by goal
Shop by compound
Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
Principal office: 1712 Pioneer Ave., Ste. 500, Cheyenne, WY 82001, USA
© 2026 New-U Research Compounds · new-u.io
[image: New-U Research Compounds on PepFinder, PepFinder rating 8.4 out of 10, store checked]